Application of headleaf loosestrife herb pharmacodynamic substance in preparation of new coronavirus resisting drug

Abstract

The invention discloses an application of a headleaf loosestrife herb pharmacodynamic substance in preparation of a new coronavirus resisting drug. A headleaf loosestrife herb aqueous extract, a headleaf loosestrife herb 30% alcohol extract, a headleaf loosestrife herb 60% alcohol extract and a headleaf loosestrife herb 85% alcohol extract have activity of inhibiting novel coronavirus pneumonia drug target Cathepsin L protease. When the concentration of single compounds of hypericin, naringenin, dihydroquercetin, quercitrin, eriodictyol and naringenin chalcone in the headleaf loosestrife herb is 0.1 mg / mL, the inhibition effects on Cathepsin L protease are 79.4%, 28.1%, 18.1%, 16.3%, 14.3% and 22.2% respectively. The headleaf loosestrife herb pharmacodynamic substance can be used for preparing a novel coronavirus pneumonia Cathepsin L protease inhibitor, a novel coronavirus pneumonia resisting drug and a novel coronavirus pneumonia preventing and treating drug.

Description

technical field [0001] The invention relates to the field of pharmaceutical technology, in particular to the application of different solvent extracts and monomer compounds of Daguoluhuang in the preparation of anti-new coronavirus drugs. [0002] technical background [0003] The new coronavirus (SARS-CoV-2) belongs to the single-stranded RNA positive-strand enveloped β-coronavirus. After invading the human body through droplets, contact, and feces, it quickly attacks multiple organs such as the lungs, heart, kidneys, and intestines, causing Multiple organ failure, eventually leading to death. During the SARS-CoV-2 pandemic, the viral genome accumulated a variety of mutations, such as the VOC B.1.617.2 lineage (Delta variant) is a virus strain that is highly fused and prone to syncytia, due to the P681R mutation that promotes furin Protease (furin)-mediated cleavage of the spike protein (S protein) accelerates cell-cell fusion and promotes B.1.617. resistance to neutralizin...

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is to provide an application of different solvent extracts and monomer compounds of Daguoluhuang in the preparation of Cathepsin L protease inhibitor anti-new coronavirus drugs, so as to overcome the scarcity of effective drugs for the existing treatment of new coronavirus pneumonia deficiencies, providing patients with new drug options

Images